NYSE · LLY
Eli Lilly and Company
$1,437.74+$64.04 (+4.66%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
NASDAQ · ACOR · USD
Stock price, earnings
Quote as of Apr 11, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.27% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Acorda Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $31.05M+6.7% vs estimate |
THE ANALYST VIEW
19 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,437.74+$64.04 (+4.66%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$280.03+$4.83 (+1.76%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 0.37% below the high.
$294.79+$4.00 (+1.38%)
AbbVie Inc.’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$0.00-$0.00 (-85.71%)
RCMW Group, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.51-$0.16 (-23.29%)
Lucy Scientific Discovery Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.99% below the high.
$0.00$0.00 (0.0%)
NewBridge Global Ventures, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
High Fusion Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
PotNetwork Holdings, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
